Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial have?
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial has 142 citations in the OpenAlex counts ScholarIQ stores.
When was Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial published?
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial has 2022 year in the ScholarIQ index.
What is the open-access status of Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial?
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial has bronze oa status in the ScholarIQ index.
What is the DOI of Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial?
The DOI for Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial is on the source record.
What is the PMID of Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial?
The PMID for Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial is on the source record.
What is the OpenAlex record for Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial?
The OpenAlex for Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial is on the source record.